Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

Benjamin P. Levy, Giuseppe Giaccone, Benjamin Besse, Enriqueta Felip, Marina Chiara Garassino, Manuel Domine Gomez, Pilar Garrido, Bilal Piperdi, Santiago Ponce-Aix, Daniel Menezes, Kyle J. MacBeth, Alberto Risueño, Ruta Slepetis, Xiaoling Wu, Abderrahim Fandi, Luis Paz-Ares

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Fingerprint

Dive into the research topics of 'Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences